MICS does not harm the cornea

Article

Microincision cataract surgery (MICS) does not degrade the optical quality of the cornea or induce a modification in corneal astigmatism.

Microincision cataract surgery (MICS) does not degrade the optical quality of the cornea or induce a modification in corneal astigmatism, according to a report published in the January issue of the Journal of Cataract and Refractive Surgery.

Jorge Alio and colleagues from VISSUM, Instituto Oftalmologico de Alicante, Spain conducted a study to examine the effect of MICS on the optical quality of the cornea, characterized in terms of Seidel aberrations. A total of 25 eyes from 25 patients, with nuclear or corticonuclear cataract of grade 2+ to 4+, were enrolled.

MICS was performed using low ultrasound power through a 1.6 to 1.8 mm clear corneal incision placed on the axis of the positive corneal meridian. All eyes received an Acri.Smart 48S (Acri.Tec) intraocular lens (IOL). Seidel aberration root-mean-square (RMS) values were obtained with a 6 mm aperture using the CSO topographer (Costruzione Strumenti Oftalmici) preoperatively and one and three months postoperatively.

The total RMS following MICS decreased from a preoperative mean of 2.15±2.51 µm to 1.96±2.01 µm postoperatively; this decrease was not considered to be statistically significant. Furthermore, the difference between the preoperative corneal astigmatism (-0.80±0.76 D) and postoperative astigmatism (-0.63±0.62 D) was also not considered to be statistically significant, nor were the differences in Seidel aberrations, coma or higher-order aberrations.

The results of this study suggest that MICS does not degrade the optical quality of the cornea or induce a modification in corneal astigmatism.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.